ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,221.42
      -0.02%
      US Tech 100
      17,716.80
      0.19%
      Dow Jones
      39,431.51
      -0.21%
      Brent Oil
      83.255
      0.05%
      Bitcoin
      62,469.31
      -0.69%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. NewAmsterdam Pharma Company NV (NAMS)

      7. NewAmsterdam Pharma Company NV (NAMS) News

      NAMS

      NewAmsterdam Pharma Comp... (NAMS)

      NewAmsterdam Pharma Company NV
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:NAMS
      DateTimeSourceHeadlineSymbolCompany
      05/09/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsNASDAQ:NAMSNewAmsterdam Pharma Company NV
      05/03/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSNewAmsterdam Pharma Company NV
      05/02/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024NASDAQ:NAMSNewAmsterdam Pharma Company NV
      04/09/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSNewAmsterdam Pharma Company NV
      04/01/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
      03/25/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressNASDAQ:NAMSNewAmsterdam Pharma Company NV
      03/12/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDNASDAQ:NAMSNewAmsterdam Pharma Company NV
      02/28/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:NAMSNewAmsterdam Pharma Company NV
      02/26/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in MarchNASDAQ:NAMSNewAmsterdam Pharma Company NV
      02/13/202410:40PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSNewAmsterdam Pharma Company NV
      02/13/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSNewAmsterdam Pharma Company NV
      02/01/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:NAMSNewAmsterdam Pharma Company NV
      01/08/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of DirectorsNASDAQ:NAMSNewAmsterdam Pharma Company NV
      01/04/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces 2024 Strategic PrioritiesNASDAQ:NAMSNewAmsterdam Pharma Company NV
      11/13/20238:00AMGlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial HighlightsNASDAQ:NAMSNewAmsterdam Pharma Company NV
      10/23/20238:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
      09/21/20237:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 MutationNASDAQ:NAMSNewAmsterdam Pharma Company NV
      09/20/20238:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:NAMSNewAmsterdam Pharma Company NV
      08/14/20234:01PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
      08/07/20237:15AMGlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial HighlightsNASDAQ:NAMSNewAmsterdam Pharma Company NV
      07/25/20234:01PMGlobeNewswire Inc.NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSNewAmsterdam Pharma Company NV
      06/09/20234:01PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
      06/06/202311:25PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
      06/06/20234:01PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
      06/05/20237:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese PatientsNASDAQ:NAMSNewAmsterdam Pharma Company NV
      06/03/202312:15PMGlobeNewswire Inc.NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023NASDAQ:NAMSNewAmsterdam Pharma Company NV
      05/31/20238:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Present at Jefferies Healthcare ConferenceNASDAQ:NAMSNewAmsterdam Pharma Company NV
      05/23/20238:00AMGlobeNewswire Inc.NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023NASDAQ:NAMSNewAmsterdam Pharma Company NV
      05/08/20238:00AMGlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial HighlightsNASDAQ:NAMSNewAmsterdam Pharma Company NV
      04/24/20238:00AMGlobeNewswire Inc.NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial HypercholesterolemiaNASDAQ:NAMSNewAmsterdam Pharma Company NV
       Showing the most relevant articles for your search:NASDAQ:NAMS

      Your Recent History

      BIT
      P1YGH3
      NLBNPIT1YGH3 20240621 35
      Delayed Upgrade Clock